• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23533 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ublituximab (multiple sclerosis) – 2nd Addendum to Project A24-13]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, treatment-naive patients) – Assessment according to §35a SGB V (1), Sentence 11]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Danicopan (paroxysmal haemoglobinuria) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (high-grade malignant glioma in paediatric patients aged 1 year and older, in combination with trametinib) – Assessment according to §35a SGB V (1), Sentence 11]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib and trametinib (malignant glioma with BRAF V600E mutation in children aged 1 year and older) – Assessment according to §35a SGB V (1), Sentence 11]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria); assessment according to §35a Social Code Book (SGB) V; estimation of patient numbers]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gozetotide (positron emission tomography, prostate cancer [mCRPC]) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease) - Addendum to Project A24-27]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fruquintinib (colorectal cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, adjuvant) – benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (unresectable or metastatic urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fezolinetant (vasomotor symptoms in menopause) – Addendum to Project A24-15]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ublituximab (multiple sclerosis) – Addendum to Project A24-13]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vadadustat (anaemia associated with chronic kidney disease on dialysis) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Futibatinib (cholangiocarcinoma) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (solid tumours) - Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (thyroid cancer) - Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for risdiplam: Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third addendum to Commission A21-131]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndromes) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis, adolescents 12 years and older) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Quality indicators for the care and services provided in long-term left ventricular assist device implantation programs]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Paclitaxel-coated balloon dilatation in recurrent bulbar urethral strictures]
2024     Andalusian Health Technology Assessment Area (AETSA) [Liquid biopsy in lung neoplasms: diagnosis, prognosis and treatment adequacy]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism by MS/MS. Update: Carnitine uptake deficiency; very long chain acyl-CoA dehydrogenase deficiency]
2024     NIHR Health Technology Assessment programme Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluation
2024     National Institute for Health and Care Excellence (NICE) CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. NICE diagnostics guidance 59
2024     National Institute for Health and Care Excellence (NICE) Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus. NICE interventional procedures guidance 789
2024     National Institute for Health and Care Excellence (NICE) Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury. NICE interventional procedures guidance 792
2024     National Institute for Health and Care Excellence (NICE) Caval valve implantation for tricuspid regurgitation. NICE interventional procedures guidance 791
2024     National Institute for Health and Care Excellence (NICE) Phrenic nerve pacing for congenital central hypoventilation syndrome. NICE interventional procedures guidance 790
2024     National Institute for Health and Care Excellence (NICE) Single-step scaffold insertion for repairing symptomatic chondral knee defects. NICE interventional procedures guidance 793
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal). NICE technology appraisal guidance 966
2024     National Institute for Health and Care Excellence (NICE) Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 968
2024     National Institute for Health and Care Excellence (NICE) Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal). NICE technology appraisal guidance 969
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over. NICE technology appraisal guidance 967
2024     National Institute for Health and Care Excellence (NICE) Remdesivir and tixagevimab plus cilgavimab for treating COVID-19. NICE technology appraisal guidance 971
2024     National Institute for Health and Care Excellence (NICE) Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments. NICE technology appraisal guidance 970
2024     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. NICE technology appraisal guidance 975
2024     National Institute for Health and Care Excellence (NICE) Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 974
2024     National Institute for Health and Care Excellence (NICE) Atogepant for preventing migraine. NICE technology appraisal guidance 973
2024     National Institute for Health and Care Excellence (NICE) Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal). NICE technology appraisal guidance 972
2024     National Institute for Health and Care Excellence (NICE) Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 978
2024     National Institute for Health and Care Excellence (NICE) Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. NICE technology appraisal guidance 977
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 976
2024     National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 980
2024     National Institute for Health and Care Excellence (NICE) Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation. NICE technology appraisal guidance 979
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 983
2024     National Institute for Health and Care Excellence (NICE) Voxelotor for treating haemolytic anaemia caused by sickle cell disease. NICE technology appraisal guidance 981
2024     National Institute for Health and Care Excellence (NICE) Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal). NICE technology appraisal guidance 982
2024     National Institute for Health and Care Excellence (NICE) Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 984
2024     National Institute for Health and Care Excellence (NICE) Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma. NICE technology appraisal guidance 985
2024     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal). NICE technology appraisal guidance 987
2024     National Institute for Health and Care Excellence (NICE) Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over. NICE technology appraisal guidance 986
2024     National Institute for Health and Care Excellence (NICE) Tenecteplase for treating acute ischaemic stroke. NICE technology appraisal guidance 990
2024     National Institute for Health and Care Excellence (NICE) Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B. NICE technology appraisal guidance 989
2024     National Institute for Health and Care Excellence (NICE) Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis. NICE technology appraisal guidance 988
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. NICE technology appraisal guidance 992
2024     National Institute for Health and Care Excellence (NICE) Burosumab for treating X-linked hypophosphataemia in adults. NICE technology appraisal guidance 99
2024     National Institute for Health and Care Excellence (NICE) Abaloparatide for treating osteoporosis after menopause. NICE technology appraisal guidance 991
2024     National Institute for Health and Care Excellence (NICE) Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal). NICE technology appraisal guidance 994
2024     National Institute for Health and Care Excellence (NICE) Linzagolix for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 996
2024     National Institute for Health and Care Excellence (NICE) Relugolix for treating hormone-sensitive prostate cancer. NICE technology appraisal guidance 995
2024     National Institute for Health and Care Excellence (NICE) Risankizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 998
2024     National Institute for Health and Care Excellence (NICE) Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 997
2024     National Institute for Health and Care Excellence (NICE) Vibegron for treating symptoms of overactive bladder syndrome. NICE technology appraisal guidance 999
2024     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment. NICE technology appraisal guidance 1001
2024     National Institute for Health and Care Excellence (NICE) Iptacopan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 1000
2024     National Institute for Health and Care Excellence (NICE) Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. NICE technology appraisal guidance 1005
2024     National Institute for Health and Care Excellence (NICE) Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion. NICE technology appraisal guidance 1004
2024     National Institute for Health and Care Excellence (NICE) Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over. NICE technology appraisal guidance 1003
2024     National Institute for Health and Care Excellence (NICE) Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over. NICE technology appraisal guidance 1002
2024     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal). NICE technology appraisal guidance 1006
2024     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. NICE technology appraisal guidance 1007
2024     National Institute for Health and Care Excellence (NICE) Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments. NICE technology appraisal guidance 1008
2024     National Institute for Health and Care Excellence (NICE) Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. NICE technology appraisal guidance 1009
2024     NIHR Health Technology Assessment programme Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
2024     NIHR Health Technology Assessment programme Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Magnetic resonance neurography in peripheral neuropathy or plexopathy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: overview – comparison, based on health profile, of the use of primary care medical services by persons registered with a family physician and those who are not]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: COVID-19 - optimal use of parmacological treatments]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Public health preparedness for mass gatherings
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: hormone therapy for the management of the clinical manifestations of menopause]
2024     NIHR Health Technology Assessment programme Specific phobias in children with moderate to severe intellectual disabilities: SPIRIT, an adaptation and feasibility study
2024     NIHR Health Technology Assessment programme Antidepressants for pain management in adults with chronic pain: a network meta-analysis
2024     NIHR Health Technology Assessment programme MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis
2024     Penn Medicine Center for Evidence-based Practice (CEP) Impact of workforce racial and ethnic diversity on patient health and healthcare outcomes
2024     NIHR Health Services and Delivery Research programme Consequences of how third sector organisations are commissioned in the NHS and local authorities in England: a mixed-methods study
2024     NIHR Health Technology Assessment programme Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
2024     NIHR Health Technology Assessment programme Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2024     NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     Penn Medicine Center for Evidence-based Practice (CEP) Hyperbaric oxygen therapy for injury recovery among athletes
2024     NIHR Health Services and Delivery Research programme Routine outcomes to investigate differences between ethnic minorities and White British people presenting to emergency services for injury: the stakeholder consultation
2024     NIHR Health Technology Assessment programme Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews